Tevogen Inc. Increase (Decrease) in Accrued Liabilities
Tevogen Inc. (TVGN) reported Increase (Decrease) in Accrued Liabilities of -$272.58 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Tevogen Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$14.17K.
- Tevogen Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$258.42K, a 194.09% decline year-over-year.
- Tevogen Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $376.14K, a 34.95% increase year-over-year.
- Tevogen Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$379.14K.
- Tevogen Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$74.20K.
- Tevogen Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$681.45K.
- Tevogen Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$603.83K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$272.58K 10-Q · filed 2026-08-14 | $103.56K derived: sum of 3 quarters · filed 2026-08-14 | -$275.58K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$258.42K 10-Q · filed 2026-05-15 | $117.73K derived: sum of 2 quarters · filed 2026-05-15 | -$261.41K derived: sum of 3 quarters · filed 2026-05-15 | -$607.27K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $376.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.00K derived: sum of 2 quarters · filed 2026-03-31 | -$348.85K derived: sum of 3 quarters · filed 2026-08-14 | -$74.20K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$379.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$725.00K derived: sum of 2 quarters · filed 2026-08-14 | -$450.35K 10-Q · filed 2025-11-14 | -$171.62K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$345.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$71.21K 10-Q · filed 2026-08-14 | $207.52K derived: sum of 3 quarters · filed 2026-08-14 | -$163.13K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $274.65K 10-Q · filed 2026-05-15 | $553.37K derived: sum of 2 quarters · filed 2026-05-15 | $182.73K derived: sum of 3 quarters · filed 2026-05-15 | $393.94K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $278.72K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$91.92K derived: sum of 2 quarters · filed 2026-03-31 | $119.29K derived: sum of 3 quarters · filed 2026-03-31 | -$681.45K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$370.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$159.43K derived: sum of 2 quarters · filed 2025-11-14 | -$960.17K 10-Q · filed 2025-11-14 | -$1.10M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $211.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$589.53K 10-Q · filed 2025-08-14 | -$734.20K derived: sum of 3 quarters · filed 2025-08-14 | -$692.71K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$800.74K 10-Q · filed 2025-05-14 | -$945.41K derived: sum of 2 quarters · filed 2025-05-14 | -$903.92K derived: sum of 3 quarters · filed 2025-05-14 | -$924.17K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$144.67K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-02 | -$103.18K derived: sum of 2 quarters · filed 2025-04-02 | -$123.43K derived: sum of 3 quarters · filed 2025-04-02 | -$603.83K 10-K · filed 2025-04-02 |
| 2023-09-30 | $41.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | $21.24K derived: sum of 2 quarters · filed 2024-11-19 | -$459.16K 10-Q · filed 2024-11-19 | |
| 2023-06-30 | -$20.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$500.66K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$480.40K 10-Q · filed 2024-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |